Is Compounded Tirzepatide Safe? How to Check the Vial, the Pharmacy and the Prescriber

Quick answer

As of September 2026, compounded tirzepatide is not FDA-approved as a final product, and whether it is safe depends on who made the vial and who prescribed it, because no federal agency reviewed that specific product before it was sold. FDA states that unapproved versions "do not undergo FDA's review for safety, effectiveness and quality before they are marketed," and its page on unapproved GLP-1 drugs reports that as of May 31, 2026 it had received "more than 730 reports of adverse events associated with compounded tirzepatide," adding that such reports are likely underreported. What you can verify yourself therefore comes down to two things: the pharmacy's license and legal category, and a prescription written for you by a clinician licensed in your state.

Start with the question you are really asking

Whether you searched "is compound tirzepatide safe" or "how safe is compounded tirzepatide," you are holding, or about to order, a vial with a pharmacy label on it, and the real question is: can I trust this vial, from this pharmacy, prescribed by this clinician? No approval stands behind a compounded product, so that is the right question. FDA puts it plainly: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." So the answer is assembled from checks you run. The checklist comes first; the background that explains each check follows.

Is your compounded tirzepatide safe? Seven checks before you trust a vial

1. Find the pharmacy's name on the label and look it up with the state board of pharmacy. Search the name on the board website for the state where the pharmacy sits, and on your own state's board if it ships across state lines. California's board, for example, states that information on its website "can be accepted as verification of a license, per Business and Professions Code section 4106." FDA has documented compounded GLP-1 labels naming pharmacies that "do not exist." Our guide to reading a prescription label shows where each element sits.

2. Ask whether the pharmacy is a 503A pharmacy or a 503B outsourcing facility. Two legal categories, two different inspectors, two different quality standards, explained below and in our 503A versus 503B explainer.

3. Confirm that a prescription written for you by a licensed clinician was required. Federal law defines 503A compounding as preparation "for an identified individual patient based on the receipt of a valid prescription order." FDA lists, as a telehealth red flag, a company that "does not require a screening and prescription by a licensed doctor before providing medicine."

4. Look up the prescriber's license. Every state medical board runs a public search; the Medical Board of California, for example, provides "profiles for all physicians and other allied health care providers who are licensed/registered in the state of California." Search the medical board of the state where you are located. Our five-minute license check walks through it.

5. Ask where the active ingredient came from and what was tested. Ask, and expect written answers: Which supplier provided the tirzepatide, and is it registered with FDA? Is it the base form or a salt form? Was this batch tested for potency and sterility, and by whom? How was the beyond-use date on the label set? A pharmacy that will not answer has told you something.

6. Check that the telehealth visit was a real one. FDA's recommendation is to "obtain a prescription from their doctor and fill the prescription at a state-licensed pharmacy." A visit worth trusting takes a health history, screens you against the label's contraindications (below), tells you the product is compounded and not FDA-approved, and names the pharmacy; FDA flags a company that "does not have a licensed doctor available to answer questions after you receive your medication." See what a GLP-1 telehealth subscription must tell you.

7. Inspect what arrives. FDA recommends that patients "not use any injectable GLP-1 drug that arrives warm or with insufficient refrigeration." Check the label for spelling errors, a real pharmacy address, your own name and instructions for use.

What does "compounded" mean legally?

Compounding is legal and regulated, but differently from approved drugs, and by whom depends on the category of the compounder.

A 503A pharmacy operates under 21 U.S.C. 353a: a licensed pharmacist in a state-licensed pharmacy compounds a drug "for an identified individual patient based on the receipt of a valid prescription order," and sections 351(a)(2)(B), 352(f)(1) and 355 of the statute, the last being the new drug approval requirement, do not apply to that drug. Who watches these pharmacies? In FDA's words: "Generally, state boards of pharmacy have primary responsibility for the day-to-day oversight of state-licensed pharmacies that are not registered with FDA as outsourcing facilities."

A 503B outsourcing facility operates under 21 U.S.C. 353b: a drug "compounded by or under the direct supervision of a licensed pharmacist in a facility that elects to register as an outsourcing facility." These facilities register with FDA, are inspected by FDA and "are subject to current good manufacturing practice (CGMP) requirements. By contrast, drugs compounded by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a physician, in accordance with the conditions of section 503A of the FD&C Act, are not."

That is why check two matters: from a 503A pharmacy, the state board lookup carries the weight and the sourcing and testing questions are yours to ask, because no CGMP inspection stands behind the batch. What "not FDA-approved" does and does not mean, including why it does not mean illegal, is the subject of our companion article on compounded semaglutide; the framework applies to tirzepatide as well.

What has FDA warned about compounded tirzepatide?

FDA's page on unapproved GLP-1 drugs names specific problems rather than general worry. In the agency's own words:

• Adverse events, underreported. "FDA has received reports of adverse events related to compounded versions of semaglutide and tirzepatide. However, federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA so it is likely that adverse events from compounded versions of these drugs are underreported."
• Dosing errors. FDA's alert on compounded semaglutide states that "unfamiliarity with withdrawing medication from a vial into a syringe and coupled with confusion between different units of measurement" such as milliliters, milligrams and units "may have contributed to dosing errors." For tirzepatide, FDA "has received adverse event reports that may be related to patients prescribed compounded semaglutide or tirzepatide products in doses beyond what is in the FDA-approved drug label."
• Multi-dose vials. "Generally, FDA recommends that vials containing multiple doses of sterile medications be used within 28 days after the first use because there is an increased risk of contamination after 28 days."
• Fraudulent labels. "FDA is aware of fraudulent compounded semaglutide and tirzepatide marketed in the U.S. that contain false information on the product label. In some cases, the compounding pharmacies identified on the labels of the products do not exist."
• Salt forms. FDA has stated that semaglutide salt forms "are different active ingredients than are used in the approved drugs." Ask which form of tirzepatide your pharmacy uses.
• "Research" peptides. FDA has warned companies selling GLP-1 drugs "falsely labeled 'for research purposes' or 'not for human consumption.'" In FDA's words, "The agency urges consumers not to purchase these products which are of unknown quality and may be harmful to their health."

This is not a verdict on every vial; it is a list of the ways a vial can go wrong, and each item maps onto one of the seven checks.

Is tirzepatide safe? What the approved label says

The risks of the molecule itself are documented in the prescribing information for the approved tirzepatide products, Zepbound and Mounjaro, on DailyMed. In plain words, without frequencies:

• Boxed warning: thyroid C-cell tumors. "In rats, tirzepatide causes thyroid C-cell tumors. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans."
• Contraindications. A "personal or family history of medullary thyroid carcinoma" or Multiple Endocrine Neoplasia syndrome type 2, and "known serious hypersensitivity to tirzepatide or any of the excipients."
• Warnings and precautions. Severe gastrointestinal reactions (not recommended in severe gastroparesis), acute kidney injury from dehydration, acute pancreatitis, acute gallbladder disease, low blood sugar when combined with insulin or insulin secretagogues, serious hypersensitivity reactions, pulmonary aspiration during general anesthesia or deep sedation, and diabetic retinopathy complications in people with a history of it.

Two things follow. These categories are the screening list any prescriber should walk through with you before prescribing tirzepatide in any form. And every frequency on that label was measured in clinical trials of the approved product in its own formulation and pen; no such trials exist for a compounded version, so those numbers cannot be transferred to it. Our Zepbound side effects article covers the label categories in depth.

Red flags, in FDA's words

FDA's BeSafeRx campaign warns that some online sellers offer "medicines that are dangerous or even deadly," and its unsafe signs include a site that does not require a prescription, is not licensed with your state board of pharmacy, has no licensed pharmacist to answer questions, or offers prices that seem too good to be true. FDA's telehealth red flags add a company that presents a compounded drug as if it were the FDA-approved drug, or includes a pharmacy name on the label that you think might be fraudulent. A seller that calls a compounded product a generic is making the same substitution with a different word, and how the law defines a generic drug shows why the two categories are not interchangeable. Our guides to tirzepatide online, tirzepatide near me and how to get tirzepatide apply these signs route by route; what LegitScript certification checks explains one third-party review of telehealth and pharmacy websites.

Questions to bring to a physician

NIDDK's advice is to "buy your medication from a pharmacy or online distributor approved by your health care professional," so bring these:

• Do I have any personal or family history that falls under the label's contraindications, including thyroid cancer or MEN 2?
• Have I had pancreatitis, gallbladder disease, kidney problems or severe stomach or bowel conditions that the label warns about?
• Do I take insulin or a medicine that raises insulin, and is there a surgery with anesthesia coming up?
• Is an FDA-approved tirzepatide product an option for me, and if not, why is a compounded version being considered? FDA's position is that compounded drugs "should only be used in patients whose medical needs cannot be met by an FDA-approved drug."
• How do I measure a dose from this vial with this syringe, and who do I call if I am unsure or have a side effect after hours?

The honest bottom line

Compounded tirzepatide is not FDA-approved, FDA has received hundreds of adverse event reports about it, and FDA has documented specific failure modes: dosing errors, false labels, salt forms, research-labeled peptides and warm shipments. None of that adds up to "unsafe" for every vial, and none of it adds up to "safe" for any vial. It adds up to the seven checks above and the questions for your physician. Run the checks, ask the questions, and treat any source that resists either as your answer. The same research-peptide problem now surrounds a molecule with no approval at all, covered in retatrutide side effects and the reta sold online. If a term on this page is unclear, our help center explains it.

This article is for informational purposes only and does not constitute medical advice. Compounded medications are not FDA-approved as final products. Medication is prescribed only if a licensed physician determines it is appropriate. Always consult a qualified healthcare provider about your own situation.